December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Predictive Oncology Inc. - Common Stock (NQ:POAI)

0.9650 +0.0147 (+1.55%)
Streaming Delayed Price Updated: 9:49 AM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Predictive Oncology Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Predictive Oncology Announces 1-for-15 Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025 
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugs 
From Predictive Oncology Inc.
Via GlobeNewswire
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies 
From Predictive Oncology Inc.
Via GlobeNewswire
Court Denies Renovaro Motion for an Expedited Trial in July
From Predictive Oncology Inc.
Via GlobeNewswire
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
From Renovaro Inc
Via GlobeNewswire
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
From Renovaro Inc
Via GlobeNewswire
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples 
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Predictive Oncology Inc.
Via GlobeNewswire
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
From FN Media Group LLC
Via GlobeNewswire
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs
From Predictive Oncology Inc.
Via GlobeNewswire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
From Renovaro Inc
Via GlobeNewswire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Company continues to progress toward the signing of a definitive merger agreement with Renovaro 
From Predictive Oncology Inc.
Via GlobeNewswire
Breakthroughs and Discoveries: TNON, PNPN.V, POAI, DYAI, PRSO, Drive Innovation Across Sectors
Via AB Newswire
Topics Artificial Intelligence
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
From Predictive Oncology Inc.
Via GlobeNewswire
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology
From Renovaro Inc
Via GlobeNewswire
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Closes Registered Direct Offering
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis
From Predictive Oncology Inc.
Via GlobeNewswire
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
From Predictive Oncology Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.